In January September 2012, the company had a net profit of RON3.5 million.
Its exploitation expenses remained flat at RON302.3 million (EUR68.5 million), and its operating profit increased 16%, to RON6.7 million (EUR1.5 million), Ropharma said Monday in a report to the Bucharest Stock Exchange.
Ropharma has two production units, in Targu Mures and Chisinau, where it makes nutritional supplements and medicines. The distribution company has five warehouses and 1,200 client pharmacies, besides its own drugstore network of 116 units.
Pharmaceutical sale sin Romania at distribution prices dropped 3.3% in the third quarter, to RON2.79 billion, according to Cegedim Romania.
According to the latest reports to the stock exchange, businessman Mihai Miron indirectly owns 32.24% of Ropharma. He controls 14.71% via Rimia Investments and 17.53% via ADD Pharmaceuticals. U.S.-registered Arrow Pharmaceuticals owns 31.29% in Ropharma.
Other shareholders include private pension funds AZT Viitorul Tau – Allianz, with 5.87%, and ING with 4.99%.
Ropharma shares last traded in Bucharest Thursday, at RON0.36 per share, up 2.36%.